Very recently, it has been shown that a new analog of cordycepin, NUC-7738, which is resistant to ADA, has anti-cancer activities in cancer cells, providing additional evidence for the importance of ADA in modulating the effects of this adenosine analog [45]. This evidence concerns the gene ADA and cancer.